Lung function tests, also known as pulmonary function test is used for the diagnosis of lung disorders such as asthma, respiratory infections, chronic obstructive pulmonary disease (COPD), and others. These group of tests also determine the functioning of the lungs, and the ability of a person to breath. They are also a part of tests for routine examination by the healthcare provider. The healthcare provider may recommend lung function tests to diagnose the suspected lung disease, plan the treatment, and decide whether to continue the ongoing treatment or change it and even to stop the treatment if required. Therefore, lung function test plays a vital role in the diagnosis of various respiratory diseases, and lung disorders.
Rising prevalence of lung diseases such as asthma, COPD, and others, availability of lung function test devices, and increasing demand for lung function tests are important factors accelerating the growth of the market. Technological advancements in lung testing and the growing geriatric population are also influencing the market growth. Changing lifestyle, and smoking addiction are leading to a number of lung problems such as lung cancer, which is further driving the growth of the market.
The global lung function tests market is expected to grow at a CAGR of 5.7% during the forecast period.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4828
Major Players in Lung Function Tests Market:
Some of the key players in the global market are CareFusion Corporation (U.S.), MGC Diagnostic Corporation (U.S.), General Electric Company (U.S.), Perkin Elmer (U.S., Carestream Health, Inc. (U.S.), COSMED srl (Italy), NIHON KOHDEN CORPORATION (Japan), and others.
Regional Analysis
The lung function tests market is growing at a rapid pace in the Americas owing to emphasis on healthy lifestyle, and prevention of lung diseases. Also, increasing demand for technologically advanced diagnostic devices and the presence of major market players adding fuel to the growth of the market.
In Europe, the prevalence of allergic conditions is high, especially asthma, and allergy rhinitis. Rising prevalence of allergic conditions, and extensive research and development activities on the medical devices drive the market growth.
In Asia Pacific, the increasing prevalence of asthma, chronic obstructive pulmonary disease, poor healthcare system, and availability of diagnostic services leads the market growth. According to the data from GLOBOCAN, in 2012, the age-standardized rate (ASR) of incidence of gastrointestinal diseases in Asia Pacific was 15.8 and mortality was 11.7 per 100,000 person. According to World Health Organization (WHO), the geriatric population in China in the year 2013 was 22.6 million which is expected to show a massive growth to 90.4 million in 2050.
In the Middle East & Africa, the demand for medical devices is increasing for the diagnosis of chronic diseases such as COPD and others. Rising awareness about lung diseases among the adults, and development of the healthcare sector in the African countries also drive the growth of the market.
Segmentation
The global lung function tests market is segmented on the basis of type, indication, devices, and end user.
On the basis of the type, the market is segmented into spirometry, gas diffusion test, body plethysmograph, bronchial provocation test, and others.
On the basis of the indication, the market is segmented into asthma, chronic bronchitis, respiratory infections, chronic obstructive pulmonary disease, cystic fibrosis, pneumonia, lung cancer, and others.
On the basis of the devices, the market is segmented into spirometer, breath CO monitor, oscillometer, ergospirometer, dose controlled drug nebulizer, and others.
On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/lung-function-tests-market-4828
No comments:
Post a Comment